Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02860650 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Safety, Tolerability, and Immunogenicity of Heterologous Prime-boost Regimens Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules in Healthy Adults
A Phase 1 study, sponsored by Janssen Vaccines & Prevention B.V..
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT02860650 is a Phase 1 study that has completed, run by Janssen Vaccines & Prevention B.V.. The registered enrollment target is 72 participants.
The verdict
NCT02860650, a Phase 1 study, has completed, sponsored by Janssen Vaccines & Prevention B.V..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and immunogenicity of MVA-BN-Filo and Ad26.Filo as heterologous prime-boost vaccine regimens in healthy adult participants.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Ad26.ZEBOV
- BIOLOGICAL MVA-BN-Filo
- BIOLOGICAL Ad26.Filo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2016-08 |
| Est. Completion | 2018-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02860650
The ClinicalTrials.gov registry entry for NCT02860650 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Vaccines & Prevention B.V., which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02860650 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02860650 about?
NCT02860650 is a clinical study titled "A Study to Evaluate Safety, Tolerability, and Immunogenicity of Heterologous Prime-boost Regimens Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules in Healthy Adults". The purpose of this study is to test the safety and immunogenicity of MVA-BN-Filo and Ad26.Filo as heterologous prime-boost vaccine regimens in healthy adult participants.
What is the current status of trial NCT02860650?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2016-08. Estimated completion is 2018-01.
What interventions are being tested in trial NCT02860650?
The interventions under investigation include: Placebo (BIOLOGICAL), Ad26.ZEBOV (BIOLOGICAL), MVA-BN-Filo (BIOLOGICAL), Ad26.Filo (BIOLOGICAL).
Who is sponsoring clinical trial NCT02860650?
This trial is sponsored by Janssen Vaccines & Prevention B.V., which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.